Shares of Mediclinic International PLC (LON:MDC) have been given an average recommendation of “Hold” by the ten brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is GBX 690.22 ($9.54).
Several research firms recently weighed in on MDC. Citigroup reiterated a “neutral” rating on shares of Mediclinic International in a research note on Tuesday, October 24th. UBS Group cut shares of Mediclinic International to a “neutral” rating and increased their target price for the company from GBX 600 ($8.29) to GBX 650 ($8.98) in a research note on Tuesday, January 30th. Macquarie reiterated a “neutral” rating and issued a GBX 660 ($9.12) target price on shares of Mediclinic International in a research note on Thursday, October 26th. Jefferies Group reiterated an “underperform” rating and issued a GBX 550 ($7.60) target price on shares of Mediclinic International in a research note on Friday, October 27th. Finally, Credit Suisse Group increased their price target on shares of Mediclinic International from GBX 265 ($3.66) to GBX 305 ($4.21) and gave the stock a “neutral” rating in a research report on Thursday, October 26th.
Mediclinic International (LON MDC) traded up GBX 9.20 ($0.13) during midday trading on Tuesday, hitting GBX 588 ($8.12). 1,250,000 shares of the company traded hands, compared to its average volume of 1,500,000. Mediclinic International has a twelve month low of GBX 495.40 ($6.84) and a twelve month high of GBX 890.18 ($12.30). The company has a market capitalization of $4,330.00 and a PE ratio of 6,533.33.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/20/mediclinic-international-plc-mdc-receives-consensus-rating-of-hold-from-analysts.html.
Mediclinic International Company Profile
Mediclinic International plc is an international private healthcare provider. The Company’s segments include Mediclinic Southern Africa, Mediclinic Switzerland, Mediclinic Middle East, United Kingdom and Corporate. It focuses on providing acute care and multidisciplinary healthcare services. It has interest in Spire Healthcare, a United Kingdom-based private healthcare company.
Receive News & Ratings for Mediclinic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediclinic International and related companies with MarketBeat.com's FREE daily email newsletter.